Background Although chemotherapy for prostate cancer (PCa) can improve patient survival,
some tumours are chemo-resistant. Tumour molecular profiles may help identify the …

Simple Summary The combination of androgen deprivation therapy (ADT) with docetaxel
(DX) or/and with novel anti-androgen receptor therapies have become standards for the …

Background Androgen-deprivation therapy (ADT) is standard treatment for locally advanced
or metastatic prostate cancer (PCa). Many patients develop castration resistance (castration …

Background The phase III CHAARTED trial established upfront androgen-deprivation
therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate …

Purpose: The combination of docetaxel chemotherapy and androgen deprivation therapy
(ADT) has become a standard treatment for patients with metastatic prostate cancer. The …

Prostate cancer (PCa) is a heterogeneous disease with highly variable clinical outcomes
which presents enormous challenges in the clinical management. A vast amount of …

Prostate cancer (PC) is one of the most common cancers among men worldwide, and
advanced PCs, such as locally advanced PC (LAPC) and castration-resistant PC (CRPC) …

Determining which treatment to provide to men with prostate cancer (PCa) is a major
challenge for clinicians. Currently, the clinical risk-stratification for PCa is based on clinico …

Background Better blood tests to elucidate the behaviour of metastatic castration-resistant
prostate cancer (mCRPC) are urgently needed to drive therapeutic decisions. Plasma cell …

Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …